TheraRadar
Clinical-Stage Companies / Sinocelltech

Sinocelltech

Pre-Approval PRO BETA
34
Total Trials
11
Phase 3
20
Phase 2
13
Recruiting
419
Score

Pipeline by Phase

Phase 3
11
Phase 2
20
Phase 1
18

Therapeutic Focus

COVID-19 Advanced Malignant Solid Tumor Advanced Malignant Solid Tumours SARS-CoV-2 Infection Haemophilia A

Clinical Trials (34)

NCT07437404 Phase 3 RECRUITING

Efficacy and Safety Evaluation Study of SCT800 in Previously Untreated Hemophilia A Patients.

Started: 4/26/2024

NCT07388602 Phase 3 RECRUITING

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

Started: 1/8/2026

NCT07297329 Phase 3 RECRUITING

A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Started: 12/29/2025

NCT07362459 Phase 3 RECRUITING

A Study to Evaluate the Safety and Tolerability of SCTB14 as First-Line Therapy in Non-Small Cell Lung Cancer.

Started: 12/30/2025

NCT05308576 Phase 3 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy and Safety of SCTV01E (a COVID-19 Vaccine) in Population Aged ≥18 Years

Started: 12/26/2022

NCT04171284 Phase 3 TERMINATED

SCT-I10A or Placebo Plus Docetaxel With Previously Treated Squamous Cell Non-small Cell Lung Cancer

Started: 10/22/2019

NCT06041061 Phase 3 ACTIVE NOT RECRUITING

A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years

Started: 8/13/2023

NCT03815318 Phase 3 COMPLETED

Evaluation of SCT800 in Prophylaxis Therapy on Previous Treated Patients With Severe Hemophilia A

Started: 1/21/2019

NCT07562022 Phase 3 NOT YET RECRUITING

A Study to Evaluate the Safety and Efficacy of SCTB35 in Combination With Lenalidomide in Patients With Relapsed or Refractory Follicular Lymphoma

Started: 5/1/2026

NCT07244510 Phase 2 RECRUITING

Efficacy and Safety of SCT650C in Participants With Moderate to Severe Hidradenitis Suppurativa

Started: 12/16/2025

NCT04644185 Phase 2 TERMINATED

The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

Started: 3/27/2021

NCT05308602 Phase 2 WITHDRAWN

A Study to Evaluate the Immunogenicity and Safety of SCTV01C and SCTV01E (Two Recombinant Protein COVID-19 Vaccines) in Population Aged ≥12 Years

Started: 4/1/2022

NCT05239975 Phase 2 WITHDRAWN

A Study of the Immunogenicity and Safety of SCTV01C in Population Aged ≥12 Years and Previously Vaccinated With Inactivated COVID-19 Vaccine

Started: 4/25/2022

NCT05652543 Phase 2 COMPLETED

A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine

Started: 1/5/2023

NCT06197009 Phase 2 NOT YET RECRUITING

Efficacy and Safety of SCT650C in Participants With Axial Spondyloarthritis

Started: 7/1/2024

NCT04709328 Phase 2 NOT YET RECRUITING

To Evaluate SCTA01 Treatment of High-risk Outpatients With COVID-19

Started: 3/28/2021

NCT06672536 Phase 1 RECRUITING

Multicenter, Phase I/II Study to Evaluate the Safety, Tolerability, PK and Efficacy of SCT520FF in Patients With nAMD

Started: 11/26/2024

NCT07050641 Phase 1 RECRUITING

Phase I/II Study of SCTB39-1 in Advanced Solid Tumours

Started: 6/23/2025

NCT06841042 Phase 1 RECRUITING

A Study of SCTB35 in Patients with Systemic Lupus Erythematosus

Started: 2/1/2025

NCT06754605 Phase 1 RECRUITING

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Respiratory Syncytial Virus Vaccine

Started: 2/6/2025

NCT06600022 Phase 1 RECRUITING

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB41 in Adult Patients with Advanced Malignant Solid Tumours.

Started: 10/10/2024

NCT06252298 Phase 1 RECRUITING

A Clinical Study of SCTC21C in Participants With CD38+ Hematologic Malignancies

Started: 2/28/2024

NCT07077252 Phase 1 NOT YET RECRUITING

Phase I/II Study of SCTB39G in Advanced Solid Tumours

Started: 7/28/2025

NCT06801509 Phase 1 NOT YET RECRUITING

A Study to Evaluate the Safety, Tolerability, and Immunogenicity of a Recombinant Herpes Zoster Vaccine

Started: 2/15/2025

NCT06774664 Phase 1 NOT YET RECRUITING

A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases

Started: 1/1/2025

NCT06769984 Phase 1 NOT YET RECRUITING

A Study of SCTT11 in Healthy Participants and Participants with Thyroid Eye Disease.

Started: 2/19/2025

NCT06318884 Phase 1 NOT YET RECRUITING

A First-in-human Study of SCTB35 in Patients With Relapse/Refractory B-cell Non-Hodgkin Lymphoma

Started: 4/1/2024

NCT06304818 Phase 1 NOT YET RECRUITING

Aims to Explore the Safety, Tolerability, and Preliminary Efficacy of SCTB14 in Adult Patients With Advanced Malignant Solid Tumours.

Started: 4/30/2024

NCT05148091 Phase 1 COMPLETED

The Safety, Tolerability and Immunogenicity of COVID-19 Vaccine (SCTV01C) in Healthy, Unvaccinated Adults

Started: 12/1/2021

NCT05156645 Phase 1 WITHDRAWN

A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19

Started: 1/15/2022

NCT04483375 Phase 1 COMPLETED

Safety, Tolerability and Pharmacokinetics of SCTA01, an Anti-SARS-CoV-2 Monoclonal Antibody, in Healthy Chinese Subjects

Started: 7/24/2020

NCT03917628 Phase 1 COMPLETED

Pharmacokinetics and Safety in Healthy Volunteers

Started: 5/29/2019

NCT02206308 Phase 1 COMPLETED

Safety, Pharmacokinetics and Pharmacodynamics of Recombinant Chimeric Anti-CD20 Monoclonal Antibody in Patients With B-cell Non-Hodgkin's Lymphoma.

Started: 5/1/2012

NCT07538154 Phase 1 NOT YET RECRUITING

A Clinica Study of SCTC21C in Participants With Systemic Lupus Erythematosus

Started: 4/1/2026

Drug Candidates

SCT800 prophylaxis and treatment for bleeding events SCTC21C Bortezomib Dexamethasone Cyclophosphamide Lenalidomide SCTB14 Pembrolizumab SCT650C SCTA01
Activity Status: Active
Last Trial Started: 5/1/2026
Last Trial Ended: 1/15/2024
Trials (12 months): 8
Completed Trials: 6
Data sourced from ClinicalTrials.gov. This company has no FDA-approved drugs.